How can companies successfully engage with stakeholders to support better access to treatment for patients? In this Pharmaceutical Executive article, Andrew Butcher and Brian Kennedy, Executive Director of Alliance for Patient Access, outline six steps that help maximize the prospects for success in light of the evolving dynamics in stakeholder relationships.
Click here to read the article.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.